Adaptive and innovative Radiation Treatment FOR improving Cancer treatment outcomE (ARTFORCE); a randomized controlled phase II trial for individualized treatment of head and neck cancer

Jolien Heukelom, Olga Hamming, Harry Bartelink, Frank Hoebers, Jordi Giralt, Teresa Herlestam, Marcel Verheij, Michiel van den Brekel, Wouter Vogel, Nick Slevin, Eric Deutsch, Jan-Jakob Sonke, Philippe Lambin, Coen Rasch, Jolien Heukelom, Olga Hamming, Harry Bartelink, Frank Hoebers, Jordi Giralt, Teresa Herlestam, Marcel Verheij, Michiel van den Brekel, Wouter Vogel, Nick Slevin, Eric Deutsch, Jan-Jakob Sonke, Philippe Lambin, Coen Rasch

Abstract

Background: Failure of locoregional control is the main cause of recurrence in advanced head and neck cancer. This multi-center trial aims to improve outcome in two ways. Firstly, by redistribution of the radiation dose to the metabolically most FDG-PET avid part of the tumour. Hereby, a biologically more effective dose distribution might be achieved while simultaneously sparing normal tissues. Secondly, by improving patient selection. Both cisplatin and Epidermal Growth Factor Receptor (EGFR) antibodies like Cetuximab in combination with Radiotherapy (RT) are effective in enhancing tumour response. However, it is unknown which patients will benefit from either agent in combination with irradiation. We will analyze the predictive value of biological markers and (89)Zr-Cetuximab uptake for treatment outcome of chemoradiation with Cetuximab or cisplatin to improve patient selection.

Methods: ARTFORCE is a randomized phase II trial for 268 patients with a factorial 2 by 2 design: cisplatin versus Cetuximab and standard RT versus redistributed RT. Cisplatin is dosed weekly 40 mg/m(2) for 6 weeks. Cetuximab is dosed 250 mg/m(2) weekly (loading dose 400 mg/m(2)) for 6 weeks. The standard RT regimen consists of elective RT up to 54.25 Gy with a simultaneous integrated boost (SIB) to 70 Gy in 35 fractions in 6 weeks. Redistributed adaptive RT consists of elective RT up to 54.25 Gy with a SIB between 64-80 Gy in 35 fractions in 6 weeks with redistributed dose to the gross tumour volume (GTV) and clinical target volume (CTV), and adaptation of treatment for anatomical changes in the third week of treatment.Patients with locally advanced, biopsy confirmed squamous cell carcinoma of the oropharynx, oral cavity or hypopharynx are eligible.Primary endpoints are: locoregional recurrence free survival at 2 years, correlation of the median (89)Zr-cetuximab uptake and biological markers with treatment specific outcome, and toxicity. Secondary endpoints are quality of life, swallowing function preservation, progression free and overall survival.

Discussion: The objective of the ARTFORCE Head and Neck trial is to determine the predictive value of biological markers and (89)Zr-Cetuximab uptake, as it is unknown how to select patients for the appropriate concurrent agent. Also we will determine if adaptive RT and dose redistribution improve locoregional control without increasing toxicity.ClinicalTrials.gov Identifier: NCT01504815.

Figures

Figure 1
Figure 1
Dose in the redistributed radiotherapy regimen. Transverse (left) and coronal (right) view with isodose lines. In the dose-painted redistriburtion radiotherapy regimen, the GTV-FDG-PET is defined by an automatic iso-contour at 50% of the maximum uptake in the primary tumour. This is expanded by 3mm to form the PTV-FDG-PET. The GTV-primary should at least encompass the GTV-FDG-PET and is expanded by 10mm to form the PTV-primary. The PTV-FDG-PET will receive 35 fractions to a maximum total dose of 84 Gy to 2% of the volume (PTV-FDG-PET), a minimum dose of 70 Gy and a mean dose of approximately 77 Gy. The PTV-primary outside the PTV-FDG-PET will receive 35 fractions to a total mean dose of 67 Gy (ranging from 64-70 Gy).
Figure 2
Figure 2
The ARTFORCE head & neck study design. (“tumour other” = tumour - 'tumour 50% isocontour PET’).
Figure 3
Figure 3
89Zr-Cetuximab timeline. Day −3 is three days before the first day of treatment. Between day −14 and −7, further pre-treatment evaluation is performed and the treatment planning is finalized.
Figure 4
Figure 4
Tumour imaging: FDG-PET/CT scans and 89Zr-Cetuximab-PET scans. A + B: patient with a negative 89Zr-Cetuximab scan. C + D: patient with a positive 89Zr-Cetuximab scan.

References

    1. Pignon JP, le Maitre A, Maillard E, Bourhis J. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol. 2009;92:4–14. doi: 10.1016/j.radonc.2009.04.014.
    1. Soto DE, Kessler ML, Piert M, Eisbruch A. Correlation between pretreatment FDG-PET biological target volume and anatomical location of failure after radiation therapy for head and neck cancers. Radiother Oncol. 2008;89:13–18. doi: 10.1016/j.radonc.2008.05.021.
    1. Gregoire V, Jeraj R, Lee JA, O'Sullivan B. Radiotherapy for head and neck tumours in 2012 and beyond: conformal, tailored, and adaptive? Lancet Oncol. 2012;13:e292–e300. doi: 10.1016/S1470-2045(12)70237-1.
    1. Madani I, Duprez F, Boterberg T, Van de Wiele C, Bonte K, Deron P, De Gersem W, Coghe M, De Neve W. Maximum tolerated dose in a phase I trial on adaptive dose painting by numbers for head and neck cancer. Radiother Oncol. 2011;101:351–355. doi: 10.1016/j.radonc.2011.06.020.
    1. Wu Q, Chi Y, Chen PY, Krauss DJ, Yan D, Martinez A. Adaptive replanning strategies accounting for shrinkage in head and neck IMRT. Int J Radiat Oncol Biol Phys. 2009;75:924–932. doi: 10.1016/j.ijrobp.2009.04.047.
    1. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, Jones CU, Sur R, Raben D, Jassem J. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006;354:567–578. doi: 10.1056/NEJMoa053422.
    1. Caudell JJ, Sawrie SM, Spencer SA, Desmond RA, Carroll WR, Peters GE, Nabell LM, Meredith RF, Bonner JA. Locoregionally advanced head and neck cancer treated with primary radiotherapy: a comparison of the addition of cetuximab or chemotherapy and the impact of protocol treatment. Int J Radiat Oncol Biol Phys. 2008;71:676–681. doi: 10.1016/j.ijrobp.2007.10.040.
    1. Van Loon JH, De Ruysscher AD, Ollers M, Dingemans AC, Hochstenbag M, van Dongen G, Lambin P. Non invasive imaging of cetuximab-zirconium-89 uptake with PET scans: a phase I trial. Radiother Oncol. 2011;94(suppl):S43.
    1. Zhang Y, Hong H, Cai W. PET tracers based on Zirconium-89. Curr Radiopharm. 2011;4:131–139. doi: 10.2174/1874471011104020131.
    1. Gregoire V, Eisbruch A, Hamoir M, Levendag P. Proposal for the delineation of the nodal CTV in the node-positive and the post-operative neck. Radiother Oncol. 2006;79:15–20. doi: 10.1016/j.radonc.2006.03.009.
    1. Gregoire V, Levendag P, Ang KK, Bernier J, Braaksma M, Budach V, Chao C, Coche E, Cooper JS, Cosnard G. CT-based delineation of lymph node levels and related CTVs in the node-negative neck: DAHANCA, EORTC, GORTEC, NCIC, RTOG consensus guidelines. Radiother Oncol. 2003;69:227–236. doi: 10.1016/j.radonc.2003.09.011.
    1. Bernier J, Bonner J, Vermorken JB, Bensadoun RJ, Dummer R, Giralt J, Kornek G, Hartley A, Mesia R, Robert C. Consensus guidelines for the management of radiation dermatitis and coexisting acne-like rash in patients receiving radiotherapy plus EGFR inhibitors for the treatment of squamous cell carcinoma of the head and neck. Ann Oncol. 2008;19:142–149.
    1. Lacouture ME, Mitchell EP, Piperdi B, Pillai MV, Shearer H, Iannotti N, Xu F, Yassine M. Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-Emptive Skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer. J Clin Oncol. 2010;28:1351–1357. doi: 10.1200/JCO.2008.21.7828.
    1. National Cancer Institute. Common Toxicity Criteria version 4.0. 2010. . 2012.
    1. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer. 2009;45:228–247. doi: 10.1016/j.ejca.2008.10.026.
    1. Marur S, D'Souza G, Westra WH, Forastiere AA. HPV-associated head and neck cancer: a virus-related cancer epidemic. Lancet Oncol. 2010;11:781–789. doi: 10.1016/S1470-2045(10)70017-6.
    1. Semrau R, Duerbaum H, Temming S, Huebbers C, Stenner M, Drebber U, Klussmann JP, Muller RP, Preuss SF. Prognostic impact of human papillomavirus status, survivin, and epidermal growth-factor receptor expression on survival in patients treated with radiochemotherapy for very advanced nonresectable oropharyngeal cancer. Head Neck. 2012. published online ahead of print - october 2012.
    1. de Jong MC, Pramana J, van der Wal JE, Lacko M, Peutz-Kootstra CJ, de Jong JM, Takes RP, Kaanders JH, van der Laan BF, Wachters J. CD44 expression predicts local recurrence after radiotherapy in larynx cancer. Clin Cancer Res. 2010;16:5329–5338. doi: 10.1158/1078-0432.CCR-10-0799.
    1. Lindquist D, Romanitan M, Hammarstedt L, Nasman A, Dahlstrand H, Lindholm J, Onelov L, Ramqvist T, Ye W, Munck-Wikland E. Human papillomavirus is a favourable prognostic factor in tonsillar cancer and its oncogenic role is supported by the expression of E6 and E7. Mol Oncol. 2007;1:350–355. doi: 10.1016/j.molonc.2007.08.005.
    1. de Jong MC, Pramana J, Knegjens JL, Balm AJ, van den Brekel MW, Hauptmann M, Begg AC, Rasch CR. HPV and high-risk gene expression profiles predict response to chemoradiotherapy in head and neck cancer, independent of clinical factors. Radiother Oncol. 2010;95:365–370. doi: 10.1016/j.radonc.2010.02.001.
    1. Chung CH, Parker JS, Ely K, Carter J, Yi Y, Murphy BA, Ang KK, El Naggar AK, Zanation AM, Cmelak AJ. Gene expression profiles identify epithelial-to-mesenchymal transition and activation of nuclear factor-kappaB signaling as characteristics of a high-risk head and neck squamous cell carcinoma. Cancer Res. 2006;66:8210–8218. doi: 10.1158/0008-5472.CAN-06-1213.
    1. Chung CH, Parker JS, Karaca G, Wu J, Funkhouser WK, Moore D, Butterfoss D, Xiang D, Zanation A, Yin X. Molecular classification of head and neck squamous cell carcinomas using patterns of gene expression. Cancer Cell. 2004;5:489–500. doi: 10.1016/S1535-6108(04)00112-6.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir